13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000200406
Total reported value
$798.7M
$798.7M
20 檔
33.3%
The Q1 2025 SEC filing reveals that Johnson & Johnson held a total portfolio value of $798.7M, covering 20 public equity positions.
During Q1 2025, Johnson & Johnson's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including PTGX, CVRX, MGTX) accounted for 33.3% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 34.65% | -1.98% | — | |
| 2 | CVRX | Cvrx Inc | Stock-Other | 14.68% | -3.25% | — | |
| 3 | MGTX | MeiraGTx Holdings plc | Stock-Other | 13.17% | +2.41% | — | |
| 4 | LEGN | Legend Biotech Corp-adr | Stock-Other | 8.08% | +0.69% | — | |
| 5 | RAPP | Rapport Therapeutics Inc | Stock-Other | 7.33% | +0.75% | — | |
| 6 | PRCT | Procept Biorobotics CORP | Stock-Other | 6.10% | -0.36% | — | |
| 7 | NBTX | Nanobiotix SA - Adr | Stock-Other | 5.89% | -0.06% | — | |
| 8 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 4.04% | +0.10% | — | |
| 9 | XNCR | Xencor Inc | Stock-Other | 2.33% | +0.13% | — | |
| 10 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.92% | — | — | |
| 11 | FATE | Fate Therapeutics Inc | Stock-Other | 0.78% | +0.52% | — | |
| 12 | ✓ | Rallybio CORP | Stock-Other | 0.70% | — | — | |
| 13 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.54% | -0.16% | — | |
| 14 | NNOX | Nano-X Imaging Ltd. | Stock-Other | 0.23% | -0.03% | EXIT | |
| 15 | VOR | Vor Biopharma Inc. | Stock-Other | 0.23% | — | — | |
| 16 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 0.13% | — | — | |
| 17 | LAB | Standard Biotools Inc | Stock-Other | 0.10% | -0.01% | — | |
| 18 | TORCEUR | Adicet Bio Inc | Stock-Other | 0.08% | — | — | |
| 19 | ✓ | Biomx Inc | Stock-Other | 0.02% | — | — | |
| 20 | SENS1GBP | Senseonics Holdings Inc | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc | +10.2% | — | Unchanged |
| 2 | MGTX | MeiraGTx Holdings plc | +2.7% | — | Unchanged |
| 3 | NBTX | Nanobiotix SA - Adr | +1.7% | — | Unchanged |
| 4 | CVRX | Cvrx Inc | +1.2% | — | Unchanged |
| 5 | LEGN | Legend Biotech Corp-adr | +1.2% | — | Unchanged |
| 6 | ✓ | Biomx Inc | — | — | Unchanged |
| 7 | SENS1GBP | Senseonics Holdings Inc | — | — | Unchanged |
| 8 | LYEL | Lyell Immunopharma, Inc. | 0% | — | Unchanged |
| 9 | TORCEUR | Adicet Bio Inc | 0% | — | Unchanged |
| 10 | LAB | Standard Biotools Inc | 0% | — | Unchanged |
| 11 | NNOX | Nano-X Imaging Ltd. | -0.1% | — | Unchanged |
| 12 | VOR | Vor Biopharma Inc. | -0.1% | — | Unchanged |
| 13 | ✓ | Rallybio CORP | -0.2% | — | Unchanged |
| 14 | ARWR | Arrowhead Pharmaceuticals In | -0.3% | — | Unchanged |
| 15 | FATE | Fate Therapeutics Inc | -0.7% | — | Unchanged |
| 16 | PRCT | Procept Biorobotics CORP | -1.4% | — | Unchanged |
| 17 | XNCR | Xencor Inc | -2.1% | — | Unchanged |
| 18 | CTNM | Contineum Therapeutics Inc-a | -3.5% | — | Unchanged |
| 19 | RAPP | Rapport Therapeutics Inc | -4.2% | — | Unchanged |
| 20 | NMRA | Neumora Therapeutics Inc | -4.5% | — | Unchanged |
According to official SEC Form 13F filings, Johnson & Johnson reported a total U.S. public equity portfolio value of $798.7M across 20 disclosed positions in Q1 2025.
During Q1 2025, Johnson & Johnson's top holdings by market value included PTGX (34.6%)、CVRX (14.7%)、MGTX (13.2%). The largest single position, PTGX, represented 34.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q1 2025, Johnson & Johnson made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.